Kevin Koch
Patrimonio netto: 16 M $ in data 31/08/2026
Patrimonio netto: 16 M $ in data 31/08/2026
Dr. Kevin Koch is a President, Chief Executive Officer & Director at Edgewise Therapeutics, Inc. and a Venture Partner at OrbiMed Advisors Private Equity.
He is on the Board of Directors at Edgewise Therapeutics, Inc., Encycle Therapeutics, Inc., Neurogastrx, Inc. and Skyhawk Therapeutics, Inc. Dr. Koch was previously employed as an Independent Director by Miragen Therapeutics, Inc., a Senior Vice President by Biogen, Inc., a President & Chief Scientific Officer by Array BioPharma, Inc., an Associate Director-Medicinal Chemistry by Amgen, Inc., and a Senior Research Investigator by Pfizer Inc. He also served on the board at Terremoto Biosciences, Inc., Inflammation Research Association, Inc. and Ataxion, Inc. He received his undergraduate degree from Stony Brook University, a graduate degree from the University of Rochester and a doctorate degree from the University of Rochester.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 12/08/2026 | 391.272 ( 0,36% ) | 16 M $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Amministratore Delegato | 01/08/2017 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Investitore di Private Equity | 01/05/2016 |
Encycle Therapeutics, Inc.
Encycle Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology services | Direttore/Membro del Consiglio | - |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Direttore/Membro del Consiglio | 04/01/2018 |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. BiotechnologyHealth Technology Develops novel RNA-targeting small molecule for neurology, oncology and fibrotic diseases | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company which develops drugs for oncology and genetic diseases | Direttore/Membro del Consiglio | 01/12/2023 |
| VIRIDIAN THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 28/10/2020 |
| BIOGEN INC. | Corporate Officer/Principal | 01/09/2015 |
| ARRAY TECHNOLOGIES, INC. | Fondatore | 29/11/2013 |
| ░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 14 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops & commercializes biopharmaceutical drugs | Health Technology |
Stony Brook University
Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Inflammation Research Association, Inc.
Inflammation Research Association, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in encouraging scientists, researchers, students, teachers and clinicians with an interest in inflammation biology | Commercial Services |
Ataxion, Inc.
Ataxion, Inc. BiotechnologyHealth Technology Develops novel therapies for rare, debilitating, and underserved neurologic diseases | Health Technology |
Encycle Therapeutics, Inc.
Encycle Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Health Technology |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. BiotechnologyHealth Technology Develops novel RNA-targeting small molecule for neurology, oncology and fibrotic diseases | Health Technology |
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies for skeletal muscle diseases | Health Technology |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company which develops drugs for oncology and genetic diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale